Home > Insider Trading > Filing (0001104659-22-040391)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1585608	Jaguar Health Inc.	JAGX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1008377	A Lisa Conte	C/O Jaguar Health, Inc. 200 Pine Street, Suite 400 San Francisco CA 94104	Ceo And President	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-09-13	7,968	$2.51	8,003	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted stock units	Acquisiton	2022-03-28	606,280	$0.00	606,280	$0.00
Common Stock	Restricted stock units	Acquisiton	2022-03-28	25,000	$0.00	25,000	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
606,280			No	4	A	Direct
25,000			No	4	A	Direct

Footnotes

On September 8, 2021, the issuer effected a 3-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split). Upon effectiveness of the Reverse Stock Split, every 3 shares of voting common stock was automatically converted into one share of voting common stock.
Granted pursuant to the issuer's 2014 Stock Incentive Plan.
Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
The restricted stock unit grants were approved by the issuer's board of directors on March 28, 2022.
The restricted stock units vest in three equal annual installments beginning on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice.
The restricted stock units vest upon (i) successful completion of the pivotal trial of crofelemer (Mytesi) for cancer-therapy related diarrhea and (ii) successful completion of the investigator-initiated trials in support of the proof-of-concept requirement for early access program for patient access in Europe.